{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:40:35Z","timestamp":1678560035059},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,8,26]],"date-time":"2006-08-26T00:00:00Z","timestamp":1156550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2006,8,26]],"date-time":"2006-08-26T00:00:00Z","timestamp":1156550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1007\/s10637-006-9005-8","type":"journal-article","created":{"date-parts":[[2006,8,25]],"date-time":"2006-08-25T20:24:04Z","timestamp":1156537444000},"page":"69-75","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma"],"prefix":"10.1007","volume":"25","author":[{"given":"Ulka N.","family":"Vaishampayan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lance K.","family":"Heilbrun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony F.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jawana","family":"Lawhorn-Crews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Baranowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daryn","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence E.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,8,26]]},"reference":[{"key":"9005_CR1","first-page":"869","volume-title":"Principles and practice of genitourinary oncology","author":"MH Sokoloff","year":"1997","unstructured":"Sokoloff MH, Figlin RA, de Kernion JB, Belldegrun AS (1997) Systemic immunotherapy for genitourinary neoplasms. In: Raghavan D, Scher HI, Leibel SA, Lange P (eds) Principles and practice of genitourinary oncology, Lippincott-Raven, Philadelphia, pp 869\u2013883"},{"key":"9005_CR2","first-page":"885","volume-title":"Principles and practice of genitourinary oncology","author":"RJ Motzer","year":"1997","unstructured":"Motzer RJ, Vogelzang NJ (1997) Chemotherapy for renal cell carcinoma. In: Raghavan D, Scher HI, Leibel SA, Lange P (eds) Principles and practice of genitourinary oncology, Lippincott-Raven, Philadelphia, pp 885\u2013896"},{"key":"9005_CR3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa021491","volume":"349","author":"JC Yang","year":"2003","unstructured":"Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427\u2013434","journal-title":"N Engl J Med"},{"key":"9005_CR4","doi-asserted-by":"crossref","unstructured":"Escudier B, Szczylik C, Eisen T, Stadler WM, Schwartz B, Shan M, Bukowski RM (2005) Randomized Phase III trial of the raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc ASCO (abstract #4510)","DOI":"10.1200\/jco.2005.23.16_suppl.lba4510"},{"key":"9005_CR5","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Rini BI, Michaelson MD, Redman BG, Hudes GR, Wilding G, Bukowski RM, George DJ, Kim ST, Baum CM, The SU11248 Study Group (2005) Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). Proc ASCO (abstract #4508)","DOI":"10.1200\/jco.2005.23.16_suppl.4508"},{"key":"9005_CR6","first-page":"4190","volume":"50","author":"DM Nanus","year":"1990","unstructured":"Nanus DM, Pfeffer LM, Bander NH, Bahri S, Albino AP (1990) Antiproliferative and antitumor effects of alpha interferon in renal cell carcinomas: correlation with the expression of a kidney associated differentiation glycoprotein. Cancer Res 50:4190\u20134194","journal-title":"Cancer Res"},{"key":"9005_CR7","first-page":"5155","volume":"47","author":"YA Sidky","year":"1987","unstructured":"Sidky YA, Borden EC (1987) Inhibition of angiogenesis by interferons: effects on tumor and lymphocyte induced vascular responses. Cancer 47:5155\u20135161","journal-title":"Cancer"},{"key":"9005_CR8","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/S0022-3468(05)80308-2","volume":"8","author":"H Brem","year":"1993","unstructured":"Brem H, Gresser I, Grosfeld J, Folkman J (1993) The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J Pediatr Surg 8:1253\u20131257","journal-title":"J Pediatr Surg"},{"key":"9005_CR9","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1200\/JCO.1993.11.7.1368","volume":"11","author":"LM Minasian","year":"1993","unstructured":"Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE (1993) Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long term follow-up. J Clin Oncol 11:1368\u20131375","journal-title":"J Clin Oncol"},{"key":"9005_CR10","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1056\/NEJM199609193351207","volume":"335","author":"RJ Motzer","year":"1996","unstructured":"Motzer RJ, Bander NH, Nanus DM (1996) Renal cell carcinoma. N Engl J Med 335:865\u2013875","journal-title":"N Engl J Med"},{"key":"9005_CR11","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/NEJM199804303381804","volume":"338","author":"ME Gleave","year":"1998","unstructured":"Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F, Klotz LH, Moore MJ, Paton V, Bajamonde A (1998) Interferon gamma 1b compared with placebo in metastatic renal cell carcinoma. N Engl J Med 338:1265\u20131271","journal-title":"N Engl J Med"},{"key":"9005_CR12","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1056\/NEJM199804303381805","volume":"338","author":"S Negrier","year":"1998","unstructured":"Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal cell carcinoma. N Engl J Med 338:1272\u20131278","journal-title":"N Engl J Med"},{"issue":"4 Suppl 5","key":"9005_CR13","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1053\/j.seminoncol.2005.06.018","volume":"32","author":"R Knight","year":"2005","unstructured":"Knight R (2005) IMiDs: a novel class of immunomodulators. Semin Oncol 32(4 Suppl 5):S24\u2013S30","journal-title":"Semin Oncol"},{"key":"9005_CR14","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","volume":"177","author":"AL Moreira","year":"1993","unstructured":"Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177:1675\u20131680","journal-title":"J Exp Med"},{"key":"9005_CR15","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/bjc.1995.335","volume":"72","author":"LM Ching","year":"1995","unstructured":"Ching LM, Xu ZF, Gummer BH, Palmer BD, Joseph WR, Baguley BC (1995) Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. British J Cancer 72:339\u2013343","journal-title":"British J Cancer"},{"key":"9005_CR16","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","volume":"91","author":"RJ D'Amato","year":"1994","unstructured":"D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 91:4082\u20134085","journal-title":"Proc Natl Acad Sci"},{"key":"9005_CR17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s004170050106","volume":"236","author":"FE Kruse","year":"1998","unstructured":"Kruse FE, Jousee AM, Rohrschneider K, Becker MD, Volcker HE (1998) Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefe's Arch Clin Exp Ophthal 236:461\u2013466","journal-title":"Graefe's Arch Clin Exp Ophthal"},{"key":"9005_CR18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11912-002-0048-5","volume":"4","author":"RJ Amato","year":"2002","unstructured":"Amato RJ (2002) Thalidomide: an antineoplastic agent. Curr Oncol Rep Jan 4:56\u201362","journal-title":"Curr Oncol Rep Jan"},{"key":"9005_CR19","first-page":"1432","volume":"44","author":"AF Shields","year":"2003","unstructured":"Shields AF (2003) PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls. J Nucl Med 44:1432\u20131434","journal-title":"J Nucl Med"},{"key":"9005_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Contr Clini Trials 10:1\u201310","journal-title":"Controlled Clinical Trials"},{"key":"9005_CR21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2307\/3314658","volume":"14","author":"G Casella","year":"1987","unstructured":"Casella G (1987) Refining binomial confidence intervals. Canadian J Statistics 14:113\u2013129","journal-title":"Canadian J Statistics"},{"key":"9005_CR22","unstructured":"Mehta C, Patel N (1999) StatXact 5: statistical software for exact nonparametric inference, user manual. Cytel Software Corporation"},{"key":"9005_CR23","unstructured":"Lee E (1992) Statistical methods for survival data analysis, 2nd edn. Wiley & Sons, Inc"},{"key":"9005_CR24","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/cncr.10740","volume":"95","author":"DD Daliani","year":"2002","unstructured":"Daliani DD, Papandreou CN, Thall PF, Wang X, Perez C, Oliva R, Pagliaro L, Amato R (2002) A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer 95:758\u2013765","journal-title":"Cancer"},{"key":"9005_CR25","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/annonc\/mdf213","volume":"13","author":"B Escudier","year":"2002","unstructured":"Escudier B, Lassau N, Couanet D, Angevin E, Mesrati F, Leborgne S, Garofano A, Leboulaire C, Dupouy N, Laplanche A (2002) Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 13:1029\u20131035","journal-title":"Ann Oncol"},{"key":"9005_CR26","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.urology.2004.01.035","volume":"63","author":"PE Clark","year":"2004","unstructured":"Clark PE, Hall MC, Miller A, Ridenhour KP, Stindt D, Lovato JF, Patton SE, Brinkley W, Das S, Torti FM (2004) Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma. Urology 63:1061\u20131065","journal-title":"Urology"},{"key":"9005_CR27","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1200\/JCO.2003.01.536","volume":"21","author":"M Hernberg","year":"2003","unstructured":"Hernberg M, Virkkunen P, Bono P, Ahtinen H, Maenpaa H, Joensuu H (2003) Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. J Clin Oncol 21:3770\u20133776","journal-title":"J Clin Oncol"},{"key":"9005_CR28","doi-asserted-by":"crossref","unstructured":"Gordon MS, Manola J, Fairclough D, Cella D, Richardson R, Sosman J, Kasimis B, Dutcher JP, Wilding G (2004) Low dose interferon-\u03b12b (IFN) + thalidomide (T) in patients (pts) with previously untreated renal cell cancer (RCC). Improvement in progression-free survival (PFS) but not quality of life (QoL) or overall survival (OS). A phase III study of the Eastern Cooperative Oncology Group (E2898). Proc ASCO (abstract #4516)","DOI":"10.1200\/jco.2004.22.90140.4516"},{"key":"9005_CR29","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1200\/JCO.2004.06.132","volume":"22","author":"RJ Motzer","year":"2004","unstructured":"Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454\u2013463","journal-title":"J Clin Oncol"},{"key":"9005_CR30","doi-asserted-by":"crossref","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, O'Toole T, Park Y, Moore L (2006) A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). Proc ASCOLB (abstract #4)","DOI":"10.1200\/jco.2006.24.18_suppl.lba4"},{"key":"9005_CR31","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2002.20.5.1429","volume":"20","author":"PD Nathan","year":"2002","unstructured":"Nathan PD, Gore ME, Eisen TG (2002) Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma. J Clin Oncol 20:1429\u20131430","journal-title":"J Clin Oncol"},{"key":"9005_CR32","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","volume":"24","author":"MJ Ratain","year":"2006","unstructured":"Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505\u20132512","journal-title":"J Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-006-9005-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-006-9005-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-006-9005-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-006-9005-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:19:40Z","timestamp":1678558780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-006-9005-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,26]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["9005"],"URL":"https:\/\/doi.org\/10.1007\/s10637-006-9005-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,26]]},"assertion":[{"value":"7 April 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2006","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}